Oxford BioMedica PLC (OXBDF)

[georgejjl]

Click and read the pdf file

Several trials of CAR T-cell therapy are underway in
ovarian cancer identifying the unmet need for novel therapeutic
strategies in this disease setting.45,46 Our study suggests
that 5T4 is a valid target in ovarian cancer. Furthermore, we
have shown that polyclonal lymphocytes isolated from the
peripheral blood of patients with ovarian cancer, can be
redirected to effectively target tumor cells expressing 5T4.
Taken together, our data supports further investigation of a
5T4 CAR T-cell approach in a clinical trial setting.

All animals treated with 1×10^7 total T cells (7.6×10^5 CAR T
cells) remained alive beyond 100 days.

https://journals.lww.com/immunotherapy-journal/pages/results.aspx?txtkeywords=10.1097%2fCJI.0000000000000203

Good luck and GOD bless,

George